Log in to search using one of your social media accounts:

 

Aurobindo Pharma gets USFDA nod for oral suspension
Sevelamer Carbonate oral suspension is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 15, 2017 Category: Pharmaceuticals Source Type: news

10 Little-Known Tips For Saving Money On Health Care
Sometimes, the devil is in the details. That’s a rule that applies to health care as well; the more you know, the better off you will be. Here are 10 ways you might be surprised to know you can save money on the one truly priceless thing you have: your health. 1. Prescriptions may cost you less if you don’t use your insurance. As difficult a pill as this is to swallow, your best deal on some commonly prescribed drugs may be found by ignoring the drug coverage you pay for and instead just reaching for your wallet. Often, your insurance drug plan requires a copay that is higher than the cost of paying cash at the...
Source: Healthy Living - The Huffington Post - February 1, 2017 Category: Consumer Health News Source Type: news

Renvela (Sevelamer Carbonate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 12, 2016 Category: Drugs & Pharmacology Source Type: news

Renagel (Sevelamer Hcl) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 12, 2016 Category: Drugs & Pharmacology Source Type: news

New Phosphate Binder for Renal Failure Lowers Pill BurdenNew Phosphate Binder for Renal Failure Lowers Pill Burden
The investigational drug controls hyperphosphatemia in patients with renal failure and requires fewer daily doses than sevelamer carbonate, but it has more gastrointestinal adverse effects. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 4, 2013 Category: Consumer Health News Tags: Nephrology News Source Type: news

Phase III data for ferric citrate (Zerenex®) for hyperphosphataemia
Source: BioSpace Area: News BioSpace has reported on data from a Phase III study evaluating the safety and efficacy of ferric citrate (Zerenex®) in the treatment of hyperphosphataemia in patients with end-stage renal disease (ESRD) on dialysis (n=441).   Following a two-week washout, patients were randomised 2:1 to receive either ferric citrate or sevelamer carbonate (Renvela®) and/or calcium acetate (Phoslo®) during a 52-week safety assessment period. Following this, subjects initially randomised to ferric citrate were re-randomised to either continue treatment or switch to placebo for a 4-week effi...
Source: NeLM - News - January 29, 2013 Category: Drugs & Pharmacology Source Type: news